Improved real-life adherence of 6-monthly denosumab injections due to positive feedback based on rapid 6-month BMD increase and good safety profile

• Published in: Rheumatology international Vol. 34; no. 5; pp. 727 - 732
• Main Authors: Ringe, J. D., Farahmand, P.
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.05.2014; Springer Nature B.V
• Subjects: Aged; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - adverse effects; Bone Density - drug effects; Bone Density Conservation Agents - administration & dosage; Bone Density Conservation Agents - adverse effects; Communication; Denosumab; Drug Administration Schedule; Feedback; Female; Germany; Humans; Injections, Subcutaneous; Male; Medication Adherence; Medicine; Medicine & Public Health; Middle Aged; Osteoporosis - drug therapy; Osteoporosis - pathology; Patient Satisfaction; Physician-Patient Relations; Prospective Studies; Reinforcement (Psychology); Rheumatology; Short Communication; Time Factors; Treatment Outcome; Germany; Osteoporosis; Treatment adherence; Denosumab; Positive feedback
• ISSN: 0172-8172; 1437-160X
• DOI: 10.1007/s00296-012-2663-2

Almost 50 % of osteoporosis (OP) patients discontinue bisphosphonate (BP) therapy within 1–2 years after the start of their treatment. Denosumab’s longer dosing interval with its administration every 6 months (Q6M) as a subcutaneous (sc) injection might result in a better real-life treatment adherence and persistence than weekly or monthly oral BP treatment regimen. The objectives of this open, investigator-initiated, prospective, observational, single-center study were to evaluate adherence with denosumab 60 mg sc every 6 months (Q6M) (Prolia ® ) injections in osteoporotic patients in a routine clinical care setting and to describe whether positive feedback to OP patients based on measured bone mineral density (BMD) increases and good safety profile have an impact on patients’ real-life adherence. Results indicate that the rarity of adverse events and reduced dosage frequency together with the consistency of rapid and highly significant increases in BMD already after 6 months of denosumab therapy used as a positive reinforcement during doctor–patient interactions had a significant, positive impact on osteoporotic patient’s adherence to continue with the 6-monthly sc denosumab injections.